Xeroderma Pigmentosum: Clinical Trials

3 trials for Xeroderma Pigmentosum, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 terminated. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 2, Terminated 1

Follow Xeroderma Pigmentosum: new trials by email Literature Review of Xeroderma Pigmentosum trials Research Report on Xeroderma Pigmentosum

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62022-03-282023-09-21
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62021-10-192023-06-18
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma
Phase 2TerminatedSol-Gel Technologies, Ltd.502019-12-202026-07-21

Narrower conditions

Basal Cell Nevus Syndrome (1)  ·  Carcinoma, Basal Cell (1)  ·  Rombo syndrome (1)  ·  Syndrome (1)

Broader conditions

Congenital Abnormalities (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  DNA Repair-Deficiency Disorders (3)  ·  Genetic Diseases, Inborn (3)  ·  Metabolic Diseases (3)  ·  Neoplasms (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Photosensitivity Disorders (3)  ·  Pigmentation Disorders (3)  ·  Precancerous Conditions (3)  ·  Skin Abnormalities (3)  ·  Skin Diseases (3)  ·  Skin Diseases, Genetic (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Abnormalities, Multiple (1)

Interventions

afamelanotide (2)

Sponsors

Clinuvel Europe Limited (2)  ·  Sol-Gel Technologies, Ltd. (1)

Countries

Belgium (1)  ·  Germany (1)  ·  Spain (1)  ·  United States (1)